2011 Artikkeli
Prostaglandins
Other Lipid Mediat. 2011 Nov;96(1-4):99-108. doi:
10.1016/j.prostaglandins.2011.09.001. Epub 2011 Sep 16.
CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?
Westphal C1, Konkel A, Schunck WH.Tiivistelmä (suomennosta) Abstract
Kalaöljyt omega-3- rasvahapot kuten EPA ja DHA suojaavat rytmihäiriöltä ja äkkinäiseltä sydänperäiseltä (kardiaaliselta) kuolemalta lähinnä selvittämättömien mekanismien välityksellä. Viimeaikaiset tutkimukset ( in vitro, in vivo) ovat osoittaneet, että arakidonihappo a(AA) metabolisoivat CYP-entsyymit hyväksyvät myös vaihtoehtoisiksi substraateikseen EPA- ja DHA- rasvahapot.-
Fish oil omega-3 fatty acids such as eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) protect against arrhythmia and
sudden cardiac death by largely unknown mechanisms. Recent in vitro
and in vivo studies demonstrate that arachidonic acid (AA)
metabolizing cytochrome P450-(CYP) enzymes accept EPA and DHA as
efficient alternative substrates.
-
Dietary EPA/DHA supplementation causes a profound shift of
the cardiac CYP-eicosanoid profile from AA- to EPA- and DHA-derived
epoxy- and hydroxy-metabolites.
-
CYP2J2 and other CYP epoxygenases preferentially epoxidize
the ω-3 double bond of EPA and DHA. The corresponding metabolites,
17,18-epoxy-EPA and 19,20-epoxy-DHA, dominate the CYP-eicosanoid
profile of the rat heart after EPA/DHA supplementation.
-
The (ω-3)-epoxyeicosanoids show highly potent
antiarrhythmic properties in neonatal cardiomyocytes, suggesting
that these metabolites may specifically contribute to the
cardioprotective effects of omega-3 fatty acids.
-
This hypothesis is discussed in the context of recent
findings that revealed CYP-eicosanoid mediated mechanisms in cardiac
ischemia-reperfusion injury and maladaptive cardiac hypertrophy.
- PMID:
- 21945326
- DOI:
- 10.1016/j.prostaglandins.2011.09.001
Inga kommentarer:
Skicka en kommentar